comparemela.com

Latest Breaking News On - Teclistamab each - Page 1 : comparemela.com

Janssen Receives Positive CHMP Opinions for Novel

Talquetamab is the first therapy targeting GPRC5D to receive a positive CHMP Opinion Teclistamab, the first BCMA-targeting bispecific antibody to.

United statesRegion flamandeUnited kingdomSen zhuangEdmond chanCommittee for medicinal products human useNone of the janssen pharmaceutical companiesAmerican society of clinical oncologyEuropean medicines agencyEuropean hematology associationDrug administrationEuropean commissionJanssen research developmentJanssen pharmaceutical companies of johnsonExchange commissionClinical research

Janssen Presents First Results from Dual Bispecific

BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from.

United statesRegion flamandeEdmond chanYael cohenArnob banerjeeCompanies of johnsonCommittee for medicinal products human useJanssen research developmentHematology institute telEarly development oncologyAviv sourasky medical centerAmerican society of clinical oncologyJanssen pharmaceutical companies of johnsonEuropean medicines agencyAmerican cancer societyNone of the janssen pharmaceutical companies

Janssen Presents Longer-Term Talquetamab Follow-Up Data

Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination.

United statesCastillay leópRegion flamandeTalquetamab monotherapyMaria victoria mateosEdmond chanChris heuckJanssen pharmaceutical companies of johnsonNone of the janssen pharmaceutical companiesAmerican society of clinical oncologyEuropean commission grants marketing authorisationCompanies of johnsonAmerican cancer societyEuropean medicines agencyExchange commissionUniversity hospital of salamanca

vimarsana © 2020. All Rights Reserved.